GSK to cut 650 jobs as it shuts German vaccine plant and consolidates production in Canada

GSK announced it will close its vaccine manufacturing facility in Dresden, Germany, resulting in about 650 layoffs.

The decision follows a review and aligns with a $2.5 billion cost‑saving program launched earlier this year, aiming to concentrate vaccine production at its Canadian site.

GSK expects the remaining plant to meet future demand sustainably and competitively, noting that vaccine sales grew 8 % in the second quarter, driven by Shingrix and the RSV vaccine Arexvy.

The move reflects a broader strategy to simplify the organization and redirect capital toward late‑stage pipeline projects.